Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Camonsertib - Repare Therapeutics

Next Previous
X
Search
Drug Profile

Camonsertib - Repare Therapeutics

Alternative Names: RG-6526; RP-3500

Latest Information Update: 03 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Repare Therapeutics
  • Class Antineoplastics; Morpholines; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II Chronic lymphocytic leukaemia; Non-small cell lung cancer

Most Recent Events

  • 23 Dec 2024 Repare Therapeutics plans a registrational phase III trial in endometrial cancer in the second half of 2025
  • 12 Dec 2024 Updated efficacy data from a phase I/Ib MYTHIC trial in Solid tumour released by Repare Therapeutics
  • 12 Nov 2024 Repare Therapeutics terminates a Phase-I/II CORONADO CLL clinical trials in Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) in USA (PO) due to sponsor de-activation of all programs associated with RP-3500 (NCT05405309)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top